MS and Demyelinating Disorders

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.

In addition to the 2020 CMSC Virtual Meeting, attendees will be eligible to earn up to an additional 18 contact hours of continuing education.

Recipients of the award will be provided additional funding that will go to support porgrams for MS patients and their care partners.

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.

Women with multiple sclerosis had a greater risk of macrovascular disease than men, which was consistent with previous studies.

With an FDA decision on a BLA for the Genentech agent expected later this year, the Group Medical Director of Neuroscience at Genentech shared insight on recent findings of satralizumab in NMOSD.

Neurology News Network for the week ending May 16, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.

Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS.

The professor of neurology at NYU Langone gives her input on those who are nervous to take hospital trips, as well as the protocol for patients with neurological disorders as COVID-19 slows down.

The trio of authors from Johns Hopkins discussed the findings of a study that imply that BMI is associated with accelerated rates of ganglion cell and inner plexiform layer atrophy in those with multiple sclerosis.

Neurology News Network for the week ending May 9, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

An identified association between accelerated rates of ganglion cell and inner plexiform layer atrophy in the absence of overt metabolic comorbidities suggests that obesity may affect accelerated neurodegeneration in those with multiple sclerosis.